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The mechanism by which regulatory T cells control the germinal center response is unknown. In this issue of
Immunity, Wing et al. (2014) and Sage et al. (2014) demonstrate that CTLA-4 is a critical effector molecule
used by regulatory T cells to control the germinal center.After infection or immunization with pro-
tein antigens, the germinal center (GC)
response is initiated in secondary
lymphoid tissues. The cellular products
of the GC are long-lived plasma cells
and memory B cells that are able to
provide protection against subsequent
infection. The GC is inimitable in that
the genes encoding the B cell receptor
(BCR) are modified as the infection
ensues, providing the opportunity to
improve the specificity of the B cell
response in real time. However, the modi-
fication of the BCR by somatic hypermu-
tation within the GC is a risky business;
the random nature of the mutational pro-
cess means that the affinity by which
the BCR binds antigen can increase,
decrease, or even be altered to react
with self-antigens. Thus, a stringent
selection of GC B cells is critical for the
production of plasma cells and memory
B cells that are able to effectively control
subsequent infections.
Within the GC, B cells are subject to
a Darwinian-like selection process by
which a specialized subset of CD4+
T cells, T follicular helper (Tfh) cells,
provides ‘‘help’’ to B cells with BCRs
that recognize antigen with high affinity.
This is a competitive process during
which GC B cells with newly mutated
BCRs capture antigen from follicular
dendritic cells (FDCs) and present this
processed antigen to Tfh cells. Those B
cells with a BCR with high affinity are
able to collect more antigen from
FDCs and present more antigen to Tfh
cells. It is thought that these high-affinity
cells will preferentially engage Tfh cells
and receive proliferation and survival sig-
nals from Tfh cells, whereas B cells
bearing lower-affinity variants will not.876 Immunity 41, December 18, 2014 ª2014Positively selected B cells can differen-
tiate into antibody secreting plasma cells
or memory B cells (Crotty, 2014).
The size, specificity, and output of the
GC is influenced by a number of extrinsic
factors, such as antibody feedback,
Qa-1+CD8+ regulatory T cells, and a
specialized subset of Foxp3+ T follicular
regulatory (Tfr) cells that act within the
GC to control the magnitude of the
response (Chung et al., 2011; Crotty,
2014; Linterman et al., 2011; Wollenberg
et al., 2011). In this issue of Immunity,
Wing et al. (2014) and Sage et al. (2014)
now show that a single molecule, cyto-
toxic T-lymphocyte-associated protein 4
(CTLA-4), exerts control over multiple
aspects of regulatory T (Treg) cell-medi-
ated control of the GC.
CTLA-4 is an inhibitory receptor that
acts in opposition to the costimulatory
receptor CD28 to limit T cell immune re-
sponses. CTLA-4 and CD28 are both gly-
coproteins, which share their ligands
CD80 and CD86 that are expressed by
activated antigen-presenting cells and B
cells. CTLA-4 binds CD80 and CD86
with higher affinity and avidity than
CD28, and is thought to outcompete
CD28 for binding, thereby limiting CD28-
dependent costimulation and conse-
quently inappropriate T cell activation
(Walker and Sansom, 2011). CTLA-4-defi-
cient mice spontaneously develop a
T cell-driven lymphoproliferative syn-
drome that results in early death, which
is largely, but not completely, recapitu-
lated in mice where CTLA-4 is lost on
Treg cells only (Wing et al., 2008). Treg
cells are essential controllers of the GC
response. Mice deficient in Treg cells
form GCs in the absence of immunization
(Chung et al., 2011), suggesting that TregElsevier Inc.cells are able to control GC initiation; in
addition, a subset of Treg cells can co-
opt the Tfh differentiation pathway to
become Tfr cells that enter the GC and
control the response from within (Chung
et al., 2011; Linterman et al., 2011; Wol-
lenberg et al., 2011). CTLA-4 is an inter-
esting candidate by which Treg cells can
control the GC response, because
CTLA-4 signaling is required for the reso-
lution of the GC response (Walker et al.,
2003).
Here, Wing et al. (2014) and Sage et al.
(2014) have demonstrated that CTLA-4 is
a mechanism of suppression of the GC
response by Treg cells. These studies
demonstrate that preventing CTLA-4
signaling during protein vaccination, with
either blocking antibodies (Wing et al.,
2014) or genetic removal (Ctla4fl/fl UBC-
ERT2-Cre) (Sage et al., 2014), results in
an increased GC response, with a corre-
sponding increased number of Tfh and
Tfr cells.
To determine whether CTLA-4 on
Treg cells is important for control of the
GC response, Wing et al. generated
Ctla4fl/flFoxp3cre mice, which developed
spontaneous GCs, supporting the hy-
pothesis that CTLA-4 is an important
effector molecule on Treg cells for con-
trolling the GC response. To limit the
problem of the widespread inflammation
of Ctla4fl/flFoxp3cre mice, Wing et al.
used heterozygous Ctla4fl/+Foxp3cre
mice, whereas Sage et al. used Ctla4fl/fl
Foxp3inducible-cre to limit the depletion of
CTLA-4 on Treg cells to the time immedi-
ately prior to immunization. These animals
have a larger GC response with an
increased frequency of Tfh cells that
have elevated levels of ICOS, inter-
leukin-4 (IL-4), and Ki67, suggesting that
Figure 1. Treg Cell-Expressed CTLA-4 Controls the Germinal Center from the Outside and
Within
Treg-expressed CTLA-4 modulates the size of the GC at two distinct anatomical locations. First, at
the border of the B cell follicle where Treg cells can interact with non-GC B cells and limit their expression
of CD86. This limited expression of CD86 restricts Tfh differentiation via reduced CD28 signaling. Second,
within the GC, Tfr cells may act to directly regulate CD86 expression on B cells or act in a way that is in-
dependent of CD86 transendocytosis to limit the amount of CD28 signaling available to GC-Tfh cells.
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functional capacity of Tfh cells. In addi-
tion, they observed an increased number
of GC B cells, memory B cells, and
plasma cells specific for the immunizing
antigen. This suggests that CTLA-4
expression on Treg cells acts to limit the
size of the antigen-specific GC response.
Whether Treg and/or Tfr cells control the
antigen-specific GC response has been
a controversial aspect of the function of
these cells (Chung et al., 2011; Linterman
et al., 2011; Wollenberg et al., 2011).
But Wing et al. provide some intriguing
data, suggesting that this might reflect
the time at which Treg cells act in control-
ling the GC response. Removal of Treg
cells prior to vaccination enhances the
number of antigen-specific Tfh cells,
GC B cells, and antibodies, whereas pro-
longed depletion reduces the Ag-specific
response of both Tfh and B cells and the
production of autoantibodies increases.
Taken with the previous data, this sug-
gests that the major role for Treg-CTLA-
4 function in controlling the GC responsemight be early in the response rather
than in an established GC. To determine
whether CTLA-4-mediated Treg suppres-
sion depends on Tfr cells within the
GC, Sage et al. cotransferred Tfh and
CTLA-4-deficient Tfr cells into Cd28/
mice. Tfh cells were increased in number
after immunization and antigen-specific
antibody production was also increased,
although, surprisingly, the numbers of
GC B cells were not significantly
increased. Together, this suggests
that CTLA-4 expressed on Treg and Tfr
cells has an important role in controlling
the size of the Tfh cell population
(Figure 1), although the mechanism by
which this occurs differs between the
two studies.
That CTLA-4 is an important regulator
of T cell immunity is clear; however,
the mechanism by which it functions
has not been fully elucidated. Both a
cell-intrinsic function, through delivery of
intracellular inhibitory signals, and cell-
extrinsic role, through removal of
its ligands CD80 and CD86, have beenImmunity 41, Dproposed (Walker and Sansom, 2011).
Both studies demonstrate that CD86
expression is increased on B cells in
mice with reduced or absent Treg-
CTLA-4 expression, supporting Treg
extrinsic signaling and a mechanism of
action outside the GC. As continued
CD28 expression is required for Tfh cell
differentiation (Linterman et al., 2014),
excess stimulation through CD28 pro-
vides a plausible mechanism by which
surplus Tfh cell differentiation could
be supported when CD86 levels are
enhanced on non-GC B cells. However,
the studies differ with respect to expres-
sion of CD86 on GC B cells, with Wing
et al. reporting increased expression and
Sage et al. no change. Although the
reason for this divergence is unclear, it
might be due to the different experimental
systems used. In one study, CTLA-4 is
permanently reduced on Treg cells,
whereas in the other it is removed imme-
diately prior to immunization, possibly
altering the kinetics of transendocytosis
of CD86. Nevertheless, this discrepancy
raises the possibility that Tfr cells might
use CTLA-4 to regulate the GC response
in a manner independent of transendocy-
tosis of CD86.
One interesting implication for the
CTLA-4-mediated loss of CD86 from B
cells is the possibility that Treg cells, and
possibly Tfr cells, act directly on B cells
rather than on Tfh cells. However, it is
likely that Treg cell suppression of the
GC has more than one molecular mecha-
nism. Another candidate is IL-10, which is
produced at high levels by Tfr cells and
has been shown to directly limit the size
of the Tfh cell pool (Cai et al., 2012).
Nevertheless, these studies are the first
to describe a molecular mechanism for
how Treg cells control the GC response,
something that might have implications
for the treatment of humoral autoimmunity
and manipulating vaccine responses in
the future.REFERENCES
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Regulatory B cells have largely been reported as B cells at a developmental stage before plasma cell differ-
entiation. Matsumoto et al. (2014) report that IL-10+ plasmablasts restrain autoimmune inflammation and
suggest an ontological connection between immature B cells and regulatory plasmablasts.The phenotypic identity of regulatory B
(Breg) cells that express the immunoregu-
latory cytokine interleukin-10 (IL-10) con-
tinues to be a matter of debate within
the field. A number of overlapping pheno-
types are currently used to describe these
cells. In mice, CD5+CD1dhi B10 B cells,
CD21hiCD23hiCD24hi transitional type 2
marginal zone precursors (T2-MZP) Breg
cells, and TIM-1+ B cells are all ascribed
regulatory function in a variety of autoim-
mune, infection, and transplantation set-
tings (Ding et al., 2011; Kalampokis
et al., 2013; Rosser et al., 2014). Although
it has been suggested that T2-MZP Breg
cells might be the precursors to B10
Breg cells, the relation of these subsets
to each other, and to TIM-1+ Breg cells,
has not been studied with any rigor (Ka-
lampokis et al., 2013). A more detailed
picture of the ontology of Breg cells and
their development throughout an immune
or autoimmune response is critical
missing information needed before their
existence can be exploited for hypothe-
sized therapeutic use in restoring immune
tolerance.
One common feature of the above Breg
cell subsets is that they are thought to be
primarily Pax5+ splenic B cells at a stage
of development prior to their terminal dif-
ferentiation into plasma cells (Mauri and
Bosma, 2012). In 2012, Maseda et al.(2012) first suggested that splenic Pax5+
B10Bcells could rapidly convert into plas-
mablasts after in vivo or in vitro activation,
though they did not test the regulatory ca-
pacity of the ‘‘daughter’’ plasmablasts.
However, Shen et al. (2014) reported that
IL-10- and IL-35-expressing Breg cells
were predominantly found within the
CD138+ plasma cell pool in experimental
autoimmune encephalitis (EAE) and mu-
rine Salmonella infection. In this issue of
Immunity, Matsumoto et al. (2014) extend
these results and show that endogenous
IL-10+ plasmablasts in the draining lymph
nodes (dLNs) of mice with EAE are
important for controlling autoimmune
inflammation and that they achieve this
by inhibiting dendritic cell activation. The
authors demonstrate that mice whose B
cells are deficient in genes that control
plasma cells differentiation, Irf4 and
Prdm1, develop more severe disease
than controlmice.Moreover, they demon-
strate that Irf4 transcription is important
for the promotion of Breg cell Il-10 tran-
scription because IRF4 binds to a pro-
moter region of the Il-10 gene.
The most striking finding in the paper is
the lack of a need for splenic B cells for
Breg cell function in this model, because
plasmablast Breg cells develop and ac-
quire their function in dLNs. It has previ-
ously been suggested that the site ofmost efficient Breg cell recovery might
not always be the spleen. For instance,
in a Gnai2/ model of colitis where mice
are deficient for the G protein ai2 subunit,
the Breg cells most able to control colitis
were found in themesenteric lymph nodes
(MLNs) (Wei et al., 2005). Matsumoto et al.
(2014) examined the effects that splenec-
tomy or B-cell-specific CD62L deficiency,
a receptor that allows B cell entry to lymph
nodes, had on the development of EAE
and regulatory plasmablast generation.
Splenectomy did not affect the severity
of the disease or the generation of
CD138+CD44hi plasmablasts in the
dLNs. However, in mice lacking B cells
that expressed CD62L, plasmablasts
were undetectable in the dLNs and these
mice were unable to resolve EAE. Simi-
larly, adoptive transfer of Sell/ (encod-
ing CD62L) B cells to B-cell-deficient
mice was unable to inhibit EAE in the
same way as transfer of wild-type B cells.
In the absence of CD62L expression, B
cells could not enter the dLN and no regu-
latory plasmablasts were generated.
The redundancy of the spleen as a site
of Breg cell activity here is in marked
contrast to most Breg cell reports (Kalam-
pokis et al., 2013; Mauri and Bosma,
2012). In particular, transfer of splenic
B10 Breg cells has been reported to sup-
press EAE (Kalampokis et al., 2013). The
